Skandinaviska Enskilda Banken AB publ Sells 96 Shares of Agilent Technologies, Inc. (NYSE:A)

Skandinaviska Enskilda Banken AB publ reduced its stake in Agilent Technologies, Inc. (NYSE:A) by 0.2% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 56,682 shares of the medical research company’s stock after selling 96 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Agilent Technologies were worth $7,348,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of Agilent Technologies by 18.2% during the first quarter. Vanguard Group Inc. now owns 29,884,345 shares of the medical research company’s stock worth $4,348,471,000 after purchasing an additional 4,605,228 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Agilent Technologies by 13.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 8,542,054 shares of the medical research company’s stock worth $1,242,956,000 after acquiring an additional 1,042,926 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in Agilent Technologies by 5.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 15,064,660 shares of the medical research company’s stock valued at $1,952,832,000 after acquiring an additional 809,149 shares during the period. Meritage Group LP increased its holdings in shares of Agilent Technologies by 28.3% in the fourth quarter. Meritage Group LP now owns 2,116,862 shares of the medical research company’s stock worth $294,307,000 after acquiring an additional 467,451 shares in the last quarter. Finally, Oribel Capital Management LP acquired a new stake in shares of Agilent Technologies during the fourth quarter worth about $60,186,000. Institutional investors own 87.42% of the company’s stock.

Insider Buying and Selling at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 1,958 shares of the stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $145.00, for a total transaction of $283,910.00. Following the transaction, the chief executive officer now owns 24,118 shares in the company, valued at $3,497,110. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.33% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on A. JPMorgan Chase & Co. dropped their target price on shares of Agilent Technologies from $165.00 to $155.00 and set an “overweight” rating on the stock in a report on Thursday, May 30th. Robert W. Baird reduced their target price on shares of Agilent Technologies from $147.00 to $136.00 and set an “outperform” rating for the company in a research note on Thursday, May 30th. Wolfe Research downgraded Agilent Technologies from an “outperform” rating to a “peer perform” rating in a research note on Thursday, June 27th. TD Cowen upped their price objective on Agilent Technologies from $153.00 to $160.00 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. Finally, UBS Group lifted their target price on Agilent Technologies from $141.00 to $150.00 and gave the company a “neutral” rating in a research report on Thursday, August 22nd. One research analyst has rated the stock with a sell rating, six have given a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, Agilent Technologies currently has a consensus rating of “Moderate Buy” and a consensus price target of $141.60.

Agilent Technologies Stock Performance

A opened at $140.09 on Friday. The company has a quick ratio of 1.37, a current ratio of 1.78 and a debt-to-equity ratio of 0.36. Agilent Technologies, Inc. has a 12-month low of $96.80 and a 12-month high of $155.35. The business has a 50 day moving average of $137.87 and a 200-day moving average of $139.21. The stock has a market cap of $40.87 billion, a price-to-earnings ratio of 33.12, a PEG ratio of 6.43 and a beta of 1.05.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.06. Agilent Technologies had a return on equity of 25.26% and a net margin of 21.75%. The business had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.56 billion. During the same quarter last year, the firm posted $1.43 EPS. The company’s quarterly revenue was down 5.6% on a year-over-year basis. On average, equities research analysts expect that Agilent Technologies, Inc. will post 5.24 earnings per share for the current year.

Agilent Technologies Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 23rd. Investors of record on Tuesday, October 1st will be paid a $0.236 dividend. The ex-dividend date of this dividend is Tuesday, October 1st. This represents a $0.94 dividend on an annualized basis and a yield of 0.67%. Agilent Technologies’s dividend payout ratio (DPR) is currently 22.22%.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.